JXFGF: AI 评分 49/100 — AI 分析 (4月 2026)

Jinxin Fertility Group Limited provides assisted reproductive services (ARS) in China and the United States. The company offers artificial insemination and IVF technology, along with related medical services.

Key Facts: AI Score: 49/100 Sector: Healthcare

公司概况

概要：

Jinxin Fertility Group Limited, operating in the healthcare sector, provides assisted reproductive services in China and the U.S., focusing on artificial insemination and IVF technologies. With a presence in both markets, the company offers comprehensive services including nutrition guidance and psychological counseling, positioning itself in the growing fertility treatment market.

JXFGF是做什么的？

Founded in 2003 and headquartered in Chengdu, China, Jinxin Fertility Group Limited is an investment holding company specializing in assisted reproductive services (ARS). The company operates in both China and the United States, providing a range of fertility treatment options. Its core offerings include artificial insemination, utilizing either husband's sperm or donor sperm, and in vitro fertilization (IVF) technology, which encompasses conventional IVF and intracytoplasmic sperm injection (ICSI). Beyond these primary treatments, Jinxin Fertility offers supportive services such as nutrition guidance, traditional Chinese medicine treatments, and psychological counseling, aiming to provide holistic care to patients. The company also extends its services to gynecology, urology, internal medicine, ambulatory surgery center facilities, and ancillary medical services. Furthermore, Jinxin Fertility engages in pre-implantation genetic screening testing, investment management, management consultancy, and real estate development and operation, diversifying its revenue streams within and beyond the healthcare sector. With over 3,198 employees, Jinxin Fertility aims to address the increasing demand for fertility solutions in its key markets.

JXFGF的投资论点是什么？

Jinxin Fertility Group Limited presents a mixed investment case. The company operates in a sector with increasing demand, driven by factors such as delayed parenthood and rising infertility rates. However, its negative P/E ratio of -5.73 and a profit margin of -35.6% raise concerns about its current profitability. The company's gross margin of 34.2% indicates some ability to generate revenue over direct costs. Growth catalysts include expanding its services and geographic reach within China and the U.S. Potential risks include regulatory changes in the healthcare sector and competition from other fertility clinics. Investors should closely monitor the company's path to profitability and its ability to capitalize on growth opportunities in the ARS market.

JXFGF在哪个行业运营？

Jinxin Fertility Group Limited operates within the assisted reproductive services (ARS) industry, a segment of the healthcare sector experiencing growth due to rising infertility rates and delayed parenthood. The market is competitive, with various clinics and hospitals offering similar services. Trends include technological advancements in IVF and genetic screening, as well as increasing demand for personalized treatment plans. Jinxin Fertility competes with other players in China and the U.S., navigating regulatory landscapes and striving to differentiate through service quality and technology adoption. Competitors include GGNDF (Genea Biomedx), GNNDY (The Cooper Companies Inc).

Medical - Care Facilities

Healthcare

JXFGF有哪些增长机遇？

Expansion within China: China's large population and evolving family planning policies present a significant growth opportunity for Jinxin Fertility. By expanding its network of clinics in underserved regions and offering advanced ARS technologies, the company can tap into a growing market. The potential market size for ARS in China is estimated to reach billions of dollars in the coming years, driven by increasing awareness and disposable incomes. Timeline: Ongoing.
Strategic acquisitions and partnerships: Jinxin Fertility can pursue strategic acquisitions and partnerships to expand its service offerings and geographic reach. Collaborating with research institutions and technology providers can enhance its capabilities in areas such as genetic screening and personalized medicine. This strategy can accelerate growth and create synergies within the company's existing operations. Timeline: Ongoing.
Development of innovative ARS technologies: Investing in research and development to develop innovative ARS technologies can provide Jinxin Fertility with a competitive edge. This includes advancements in IVF techniques, genetic testing, and fertility preservation methods. By offering cutting-edge solutions, the company can attract patients seeking the most advanced treatments available. Timeline: Ongoing.
Increased focus on international patients: Jinxin Fertility can attract international patients seeking high-quality ARS services at competitive prices. By marketing its services to patients in regions with limited access to advanced fertility treatments, the company can expand its customer base and revenue streams. This strategy requires establishing partnerships with international healthcare providers and offering comprehensive support services to international patients. Timeline: Ongoing.
Leveraging digital health solutions: Implementing digital health solutions, such as telemedicine and online patient portals, can improve access to care and enhance the patient experience. These technologies can streamline the consultation process, provide remote monitoring, and facilitate communication between patients and healthcare providers. By embracing digital health, Jinxin Fertility can improve efficiency and attract tech-savvy patients. Timeline: Ongoing.

Market Cap of $0.78B reflects the company's current valuation in the market.
P/E Ratio of -5.73 indicates the company is currently not profitable.
Profit Margin of -35.6% shows significant losses relative to revenue.
Gross Margin of 34.2% demonstrates the company's ability to generate profit from its services before operating expenses.
Beta of 0.94 suggests the stock's volatility is slightly lower than the market average.

JXFGF提供哪些产品和服务？

Provides artificial insemination services using husband's or donor sperm.
Offers in vitro fertilization (IVF) technology, including conventional IVF and ICSI.
Provides nutrition guidance to support assisted reproductive services.
Offers traditional Chinese medicine treatments.
Provides psychological counseling to patients undergoing ARS.
Offers management services for medical facilities.
Provides medical services in gynecology, urology, and internal medicine.
Offers pre-implantation genetic screening testing services.

JXFGF如何赚钱？

Generates revenue through assisted reproductive services, including artificial insemination and IVF.
Earns fees from related services such as nutrition guidance, Chinese medicine treatment, and psychological counseling.
Receives income from management services provided to medical facilities.
Derives revenue from pre-implantation genetic screening testing services.

Individuals and couples seeking fertility treatments.
Patients requiring gynecological, urological, or internal medicine services.
Medical facilities seeking management services.
International patients seeking ARS services.

Established presence in both China and the United States.
Comprehensive range of assisted reproductive services.
Integration of traditional Chinese medicine with modern fertility treatments.
Focus on providing holistic care to patients.

什么因素可能推动JXFGF股价上涨？

Upcoming: Expansion of clinic network in China to meet growing demand for ARS.
Ongoing: Development and implementation of innovative ARS technologies.
Ongoing: Strategic partnerships with research institutions and technology providers.
Ongoing: Marketing efforts to attract international patients seeking fertility treatments.

JXFGF的主要风险是什么？

Potential: Regulatory changes in the healthcare sector affecting ARS practices.
Potential: Increased competition from other fertility clinics in China and the U.S.
Potential: Economic downturns impacting patient affordability and demand for ARS.
Ongoing: Negative profit margin and financial losses.
Ongoing: Risks associated with operating on the OTC market, including limited liquidity and disclosure.

JXFGF的核心优势是什么？

Presence in both China and the United States.
Comprehensive range of ARS services.
Integration of traditional Chinese medicine.
Holistic patient care approach.

JXFGF的劣势是什么？

Negative profit margin.
Reliance on regulatory approvals.
Competition from established players.
Exposure to economic fluctuations.

JXFGF有哪些机遇？

Expansion into underserved regions in China.
Strategic acquisitions and partnerships.
Development of innovative ARS technologies.
Increased focus on international patients.

JXFGF面临哪些威胁？

Regulatory changes in the healthcare sector.
Competition from other fertility clinics.
Economic downturns affecting patient affordability.
Technological advancements rendering existing services obsolete.

JXFGF的竞争对手是谁？

Genea Biomedx — Offers advanced IVF technologies. — (GGNDF)
The Cooper Companies Inc — Provides fertility and genomic solutions. — (GNNDY)
Hoya Corporation — Offers medical devices and healthcare solutions. — (HAWPY)
Merck KGaA — Provides fertility treatments and related products. — (MCRPF)
Merck & Co. Inc — Pharmaceutical company with a range of healthcare products. — (MCVEF)

Key Metrics

MoonshotScore: 49/100

Company Profile

CEO: Yang Dong
Headquarters: Chengdu, CN
Employees: 3,198
Founded: 2021

AI Insight

AI analysis pending for JXFGF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Jinxin Fertility Group Limited do?

Jinxin Fertility Group Limited is an investment holding company that provides assisted reproductive services (ARS) in China and the United States. The company offers a range of fertility treatments, including artificial insemination and in vitro fertilization (IVF). It also provides related services such as nutrition guidance, traditional Chinese medicine treatments, and psychological counseling. Jinxin Fertility operates medical facilities and offers pre-implantation genetic screening testing services, aiming to provide comprehensive fertility solutions to its patients.

What do analysts say about JXFGF stock?

Analyst information for JXFGF is not available in the provided data. Without analyst ratings or price targets, it is difficult to assess market sentiment or valuation considerations. Investors should conduct their own research and consult with financial advisors before making investment decisions. Key metrics to consider include the company's financial performance, growth prospects, and competitive landscape.

What are the main risks for JXFGF?

Jinxin Fertility Group Limited faces several risks, including regulatory changes in the healthcare sector, increased competition from other fertility clinics, and economic downturns affecting patient affordability. The company's negative profit margin and financial losses pose a significant challenge. Operating on the OTC market carries additional risks, such as limited liquidity and disclosure. Investors should carefully consider these risks before investing in JXFGF.